LONDON - GlaxoSmithKline PLC (LSE/NYSE: NYSE:GSK) announced today that the European Medicines Agency (EMA) has begun ...

Ana Botin, executive chair of Spanish bank Santander has denied reports that the company is considering leaving the British ...

FKE wants the government to adopt a stable and predictable tax regime to foster business planning saying 5,567 Kenyans have ...

Ab&B Bio-Tech has joined the stacked roster of drug developers queuing up to go public in Hong Kong, filing the paperwork for ...

PURCHASE, NY . — Rachel Ferdinando has been promoted from president of PepsiCo Foods Canada to chief executive officer of ...

The prescribing information for two respiratory syncytial virus (RSV) vaccines will now include a warning for the increased ...

A small, but positive, randomized double-blind trial of baricitinib for PMR is the first in patients with the condition to ...

Tempus AI is projected to achieve 30% YoY top line growth in Q4 2024 as presented in its preliminary results. Click here to ...

The MRHA, which overseas the safety of medicines, vaccines and healthcare devices, was accused of not acting fast enough when drugs were found to be harmful.

We recently published a list of 12 Undervalued Defensive Stocks for 2025. In this article, we are going to take a look at ...

GlaxoSmithKline (GSK – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Graham Parry from ...

Jefferies analyst Peter Welford maintained a Hold rating on GlaxoSmithKline (GSK – Research Report) today and set a price target of £14.50. The ...